Molnupiravir and remdesevir both cure FIP in cats!!!
FIP cure!
apple.news/Al1GRG3eYQFq...
apple.news/Al1GRG3eYQFq...
September 19, 2023 at 12:54 AM
Molnupiravir and remdesevir both cure FIP in cats!!!
Paxlovid may better cut risk of severe #COVID outcomes in asthma patients than molnupiravir
Paxlovid recipients were at significantly lower risk for all-cause hospitalization than those given molnupiravir.
www.cidrap.umn.edu/c...
Paxlovid recipients were at significantly lower risk for all-cause hospitalization than those given molnupiravir.
www.cidrap.umn.edu/c...
March 3, 2025 at 8:29 PM
Paxlovid may better cut risk of severe #COVID outcomes in asthma patients than molnupiravir
Paxlovid recipients were at significantly lower risk for all-cause hospitalization than those given molnupiravir.
www.cidrap.umn.edu/c...
Paxlovid recipients were at significantly lower risk for all-cause hospitalization than those given molnupiravir.
www.cidrap.umn.edu/c...
Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients www.cidrap.umn.edu/covid-19/ant...
Another large study showing the protective effect of the antiviral molnupiravir in COVID patients. However, it works best in those aged over 65, and only if given early.
Another large study showing the protective effect of the antiviral molnupiravir in COVID patients. However, it works best in those aged over 65, and only if given early.
Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
www.cidrap.umn.edu
November 22, 2024 at 12:52 AM
Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients www.cidrap.umn.edu/covid-19/ant...
Another large study showing the protective effect of the antiviral molnupiravir in COVID patients. However, it works best in those aged over 65, and only if given early.
Another large study showing the protective effect of the antiviral molnupiravir in COVID patients. However, it works best in those aged over 65, and only if given early.
Our molnupiravir work is now out after peer-review! We definitively demonstrate that molnupiravir has resulted in viable SARS-CoV-2 viruses with significant numbers of mutations, in some cases with onwards transmission of mutated viruses. www.nature.com/articles/s41...
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes - Nature
Nature - A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
www.nature.com
September 25, 2023 at 7:50 PM
Our molnupiravir work is now out after peer-review! We definitively demonstrate that molnupiravir has resulted in viable SARS-CoV-2 viruses with significant numbers of mutations, in some cases with onwards transmission of mutated viruses. www.nature.com/articles/s41...
1/ PolyBio’s Dr. Sara Cherry asserts: “Treating [the lung] with either nirmatrelvir (Paxlovid) or molnupiravir, we clear the [SARS-CoV-2] infection by 10,000-fold… while nirmatrelvir clears the infection in intestinal cultures, molnupiravir has no activity.”
December 12, 2024 at 4:05 PM
1/ PolyBio’s Dr. Sara Cherry asserts: “Treating [the lung] with either nirmatrelvir (Paxlovid) or molnupiravir, we clear the [SARS-CoV-2] infection by 10,000-fold… while nirmatrelvir clears the infection in intestinal cultures, molnupiravir has no activity.”
Study of >74K older Covid patients: When given early, the antiviral drug molnupiravir (Lagevrio) *halved* the risk of death.
Molnupiravir was effective regardless of sex, DCCI score [which measures comorbidities], age in patients over 65 years, hospitalization status, & Covid vaccination status.
Molnupiravir was effective regardless of sex, DCCI score [which measures comorbidities], age in patients over 65 years, hospitalization status, & Covid vaccination status.
Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
www.cidrap.umn.edu
November 22, 2024 at 9:14 PM
Study of >74K older Covid patients: When given early, the antiviral drug molnupiravir (Lagevrio) *halved* the risk of death.
Molnupiravir was effective regardless of sex, DCCI score [which measures comorbidities], age in patients over 65 years, hospitalization status, & Covid vaccination status.
Molnupiravir was effective regardless of sex, DCCI score [which measures comorbidities], age in patients over 65 years, hospitalization status, & Covid vaccination status.
The evidence shows that molnupiravir is not an effective drug & is likely even harmful for immunocompromised patients. 8/11
bsky.app/profile/ryan...
bsky.app/profile/ryan...
By far the largest & best randomized trial of MOV—& the only one not run by Merck—was PANORAMIC, run by UKHSA. It found no benefit from MOV & hinted MOV treatment was harmful for the immunocompromised, whose hospitalization/death rate was double in the MOV-treatment compared to non-MOV group. 6/7
December 24, 2025 at 10:03 PM
The evidence shows that molnupiravir is not an effective drug & is likely even harmful for immunocompromised patients. 8/11
bsky.app/profile/ryan...
bsky.app/profile/ryan...
I have asthma and had Paxlovid during my holiday covid case and stayed out of the hospital.
Paxlovid may better cut risk of severe COVID outcomes in asthma patients than molnupiravir www.cidrap.umn.edu/covid-19/pax...
Paxlovid may better cut risk of severe COVID outcomes in asthma patients than molnupiravir www.cidrap.umn.edu/covid-19/pax...
Paxlovid may better cut risk of severe COVID outcomes in asthma patients than molnupiravir
www.cidrap.umn.edu
March 4, 2025 at 4:19 PM
I have asthma and had Paxlovid during my holiday covid case and stayed out of the hospital.
Paxlovid may better cut risk of severe COVID outcomes in asthma patients than molnupiravir www.cidrap.umn.edu/covid-19/pax...
Paxlovid may better cut risk of severe COVID outcomes in asthma patients than molnupiravir www.cidrap.umn.edu/covid-19/pax...
BA.3.2 emerged in Nov 2024 after ~3 years of intrahost evolution with >50 new spike AA muts, but since then, it's changed very little.
Could the mutagenic drug molnupiravir (MOV) galvanize BA.3.2 into pursuing new evolutionary paths? A new 89-mut BA.3.2 sequence hints that it could. 1/11
Could the mutagenic drug molnupiravir (MOV) galvanize BA.3.2 into pursuing new evolutionary paths? A new 89-mut BA.3.2 sequence hints that it could. 1/11
December 24, 2025 at 10:03 PM
BA.3.2 emerged in Nov 2024 after ~3 years of intrahost evolution with >50 new spike AA muts, but since then, it's changed very little.
Could the mutagenic drug molnupiravir (MOV) galvanize BA.3.2 into pursuing new evolutionary paths? A new 89-mut BA.3.2 sequence hints that it could. 1/11
Could the mutagenic drug molnupiravir (MOV) galvanize BA.3.2 into pursuing new evolutionary paths? A new 89-mut BA.3.2 sequence hints that it could. 1/11
Two oral antivirals were eventually procured:
Lagevrio (molnupiravir)
Paxlovid (nirmatrelvir / ritonavir)
8/
Lagevrio (molnupiravir)
Paxlovid (nirmatrelvir / ritonavir)
8/
January 31, 2025 at 12:57 PM
Two oral antivirals were eventually procured:
Lagevrio (molnupiravir)
Paxlovid (nirmatrelvir / ritonavir)
8/
Lagevrio (molnupiravir)
Paxlovid (nirmatrelvir / ritonavir)
8/
“Molnupiravir prescribing exceeded nirmatrelvir–ritonavir [paxlovid] across all study months.”
Not quantified or elaborated on.
"Exceeded" seems an understatement: looks like ~7X more, from the ADHAC data.
Study ignores the elephant in the room - Molnupiravir has been withdrawn in most countries.
Not quantified or elaborated on.
"Exceeded" seems an understatement: looks like ~7X more, from the ADHAC data.
Study ignores the elephant in the room - Molnupiravir has been withdrawn in most countries.
February 11, 2025 at 11:28 PM
“Molnupiravir prescribing exceeded nirmatrelvir–ritonavir [paxlovid] across all study months.”
Not quantified or elaborated on.
"Exceeded" seems an understatement: looks like ~7X more, from the ADHAC data.
Study ignores the elephant in the room - Molnupiravir has been withdrawn in most countries.
Not quantified or elaborated on.
"Exceeded" seems an understatement: looks like ~7X more, from the ADHAC data.
Study ignores the elephant in the room - Molnupiravir has been withdrawn in most countries.
New data show Paxlovid outperforms molnupiravir against severe COVID-19 outcomes www.cidrap.umn.edu/covid-19/new...
New data show Paxlovid outperforms molnupiravir against severe COVID-19 outcomes
www.cidrap.umn.edu
March 23, 2024 at 12:18 AM
New data show Paxlovid outperforms molnupiravir against severe COVID-19 outcomes www.cidrap.umn.edu/covid-19/new...
Copy-back RNA synthesis by coronavirus polymerase requires helicase activity and is stimulated by remdesivir and molnupiravir | Science Advances www.science.org/doi/10.1126/...
#Coronavirus #SARS2 #COVID19 #singlemolecule #biophysics #magnetictweezers
#Coronavirus #SARS2 #COVID19 #singlemolecule #biophysics #magnetictweezers
Copy-back RNA synthesis by coronavirus polymerase requires helicase activity and is stimulated by remdesivir and molnupiravir
Helicase-driven copy-back RNA synthesis in coronaviruses reveals how antivirals trap replication intermediates.
www.science.org
June 20, 2026 at 9:05 AM
Copy-back RNA synthesis by coronavirus polymerase requires helicase activity and is stimulated by remdesivir and molnupiravir | Science Advances www.science.org/doi/10.1126/...
#Coronavirus #SARS2 #COVID19 #singlemolecule #biophysics #magnetictweezers
#Coronavirus #SARS2 #COVID19 #singlemolecule #biophysics #magnetictweezers
I've previously noted that recent molnupiravir sequences (meaning sequences whose mutations clearly originate in MOV treatment) have shown a marked trend toward positive selection of MOV mutations, i.e. MOV muts are increasing viral fitness. 1/7
bsky.app/profile/ryan...
bsky.app/profile/ryan...
Particularly interesting to me is the recent trend for *positively selected* MOV-induced mutations. Non-synonymous transition mutations score FAR higher for MOV nucleotide contexts than synonymous mutations, indicating these MOV mutations are very likely advantageous. 3/4
June 19, 2025 at 5:39 PM
I've previously noted that recent molnupiravir sequences (meaning sequences whose mutations clearly originate in MOV treatment) have shown a marked trend toward positive selection of MOV mutations, i.e. MOV muts are increasing viral fitness. 1/7
bsky.app/profile/ryan...
bsky.app/profile/ryan...
Australia, Taiwan, and Japan seem to be the major molnupiravir users these days. Sometimes it's hard to tell if a new MOV sequence is from recent MOV use or treatment from the past—like this recent FL.20.1 whose closest relatives on the tree were collected ~1 year ago. 1/4
May 25, 2025 at 10:38 AM
Australia, Taiwan, and Japan seem to be the major molnupiravir users these days. Sometimes it's hard to tell if a new MOV sequence is from recent MOV use or treatment from the past—like this recent FL.20.1 whose closest relatives on the tree were collected ~1 year ago. 1/4
It looks like in Australian Aged Care settings, they are still dispensing Molnupiravir at around 4X the rate of Paxlovid.
I thought I heard Paxlovid was preferred now? Doesnt seem to have filtered through to the outcomes.
I thought I heard Paxlovid was preferred now? Doesnt seem to have filtered through to the outcomes.
December 24, 2025 at 10:22 PM
It looks like in Australian Aged Care settings, they are still dispensing Molnupiravir at around 4X the rate of Paxlovid.
I thought I heard Paxlovid was preferred now? Doesnt seem to have filtered through to the outcomes.
I thought I heard Paxlovid was preferred now? Doesnt seem to have filtered through to the outcomes.
NICE final draft guidance for molnupiravir published: www.nice.org.uk/guidance/ind... . In a change from the draft from late 2024, and the original draft decision from 2022, it now recommends molnupiravir for subgroups at risk of severe COVID-19 for whom other treatments are unsuitable. 👀
Project documents | Molnupiravir for treating COVID-19 [ID6340] | Guidance | NICE
www.nice.org.uk
March 14, 2025 at 8:21 PM
NICE final draft guidance for molnupiravir published: www.nice.org.uk/guidance/ind... . In a change from the draft from late 2024, and the original draft decision from 2022, it now recommends molnupiravir for subgroups at risk of severe COVID-19 for whom other treatments are unsuitable. 👀
I have this really irrational hope that five days of molnupiravir for this acute Covid will cure me of #LongCovid. Almost certainly won’t happen but a girl can dream…
July 8, 2025 at 8:30 AM
I have this really irrational hope that five days of molnupiravir for this acute Covid will cure me of #LongCovid. Almost certainly won’t happen but a girl can dream…
Molnupiravir, and yeah
October 17, 2023 at 2:38 PM
Molnupiravir, and yeah
Another molnupiravir sequence from Australia showed up today w/extremely strong evidence of positive selection for MOV-induced mutations, a sign the genetic diversity created by MOV is being utilized to the virus's advantage.
Similar signals have been in almost every MOV sequence in recent months.
Similar signals have been in almost every MOV sequence in recent months.
September 12, 2025 at 11:02 PM
Another molnupiravir sequence from Australia showed up today w/extremely strong evidence of positive selection for MOV-induced mutations, a sign the genetic diversity created by MOV is being utilized to the virus's advantage.
Similar signals have been in almost every MOV sequence in recent months.
Similar signals have been in almost every MOV sequence in recent months.
Sequences resulting from failed molnupiravir treatment still show up now & then & still almost invariably display strong signs of positive selection of MOV-induced mutations (suggesting MOV muts are increasing viral fitness). Mostly from from Japan & Australia now. Latest is an NB.1.8.1 from Aug 4 👇
August 23, 2025 at 4:27 PM
Sequences resulting from failed molnupiravir treatment still show up now & then & still almost invariably display strong signs of positive selection of MOV-induced mutations (suggesting MOV muts are increasing viral fitness). Mostly from from Japan & Australia now. Latest is an NB.1.8.1 from Aug 4 👇
Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
The greatest risk reductions in COVID-related and all-cause deaths were seen among women and hospitalized patients
www.cidrap.umn.edu/c...
Photo: © Merck
The greatest risk reductions in COVID-related and all-cause deaths were seen among women and hospitalized patients
www.cidrap.umn.edu/c...
Photo: © Merck
November 21, 2024 at 10:25 PM
Antiviral COVID-19 drug molnupiravir tied to large drop in deaths in older patients
The greatest risk reductions in COVID-related and all-cause deaths were seen among women and hospitalized patients
www.cidrap.umn.edu/c...
Photo: © Merck
The greatest risk reductions in COVID-related and all-cause deaths were seen among women and hospitalized patients
www.cidrap.umn.edu/c...
Photo: © Merck
Our molnupiravir work is now typeset and open access www.nature.com/articles/s41...
A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes - Nature
A specific class of long phylogenetic branches, distinguished by a high proportion of G-to-A and C-to-T mutations, are almost exclusively found in sequences from 2022, after molnupiravir treatment was...
www.nature.com
October 26, 2023 at 11:13 AM
Our molnupiravir work is now typeset and open access www.nature.com/articles/s41...
Another day, another sequence displaying undeniable evidence of positive selection of molnupiravir-induced mutations (i.e. adaptive mutations—good for the virus, bad for the infected person).
G->A is the classic MOV mutation—and the vast majority of the positive selection is in G->A muts. 1/3
G->A is the classic MOV mutation—and the vast majority of the positive selection is in G->A muts. 1/3
January 16, 2026 at 12:26 PM
Another day, another sequence displaying undeniable evidence of positive selection of molnupiravir-induced mutations (i.e. adaptive mutations—good for the virus, bad for the infected person).
G->A is the classic MOV mutation—and the vast majority of the positive selection is in G->A muts. 1/3
G->A is the classic MOV mutation—and the vast majority of the positive selection is in G->A muts. 1/3